Multicenter Evaluation of Vancomycin Dosing

Emphasis on Obesity

Ronald G. Hall, Kenna D. Payne, Amy M. Bain, Anita P. Rahman, Sean T. Nguyen, Susan A. Eaton, Anthony J. Busti, Stephen L. Vu, Roger Bedimo

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight. Methods: This study was conducted at 2 tertiary care medical centers that did not have pharmacy-guided vancomycin dosing programs or other institutional vancomycin dosing policies or protocols. Patients who received vancomycin between July 1, 2003, and June 30, 2006, were stratified by body mass index and randomly selected from the computer-generated queries. Patients ≥18 years of age with a creatinine clearance of at least 60 mL/min who received vancomycin for at least 36 hours were included. Results: Data were collected on a random sampling of 421 patients, stratified by body mass index, who met the inclusion criteria. Most patients in each body mass index category received a fixed dose of vancomycin 2 g daily divided into 2 doses (underweight 82%, normal weight 90%, overweight 86%, and obese 91%). Adequate initial dosing (≥10 mg/kg/dose) was achieved for 100% of underweight, 99% of normal weight, 93.9% of overweight, and 27.7% of obese patients (P < .0001). Ninety-seven percent of underweight, 46% of normal weight, 1% of overweight, and 0.6% of obese patients received ≥15 mg/kg/dose recommended by several Infectious Diseases Society of America guidelines. Pharmacists also failed to correct inadequate dosing because only 3.3% of patients receiving less than 10 mg/kg/dose had their regimen changed in the first 24 hours of therapy. Conclusion: In this multicenter pilot study, obese patients routinely received inadequate empiric vancomycin using a lenient assessment of dosing. Greater efforts should be undertaken to ensure patients receive weight-based dosing because inadequate dosing can lead to subtherapeutic concentrations and potentially worse clinical outcomes.

Original languageEnglish (US)
Pages (from-to)515-518
Number of pages4
JournalAmerican Journal of Medicine
Volume121
Issue number6
DOIs
StatePublished - Jun 2008

Fingerprint

Vancomycin
Obesity
Thinness
Weights and Measures
Body Mass Index
Pharmacists
Tertiary Care Centers
Multicenter Studies
Creatinine
Body Weight
Guidelines

Keywords

  • Dosing
  • Obesity
  • Vancomycin

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hall, R. G., Payne, K. D., Bain, A. M., Rahman, A. P., Nguyen, S. T., Eaton, S. A., ... Bedimo, R. (2008). Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. American Journal of Medicine, 121(6), 515-518. https://doi.org/10.1016/j.amjmed.2008.01.046

Multicenter Evaluation of Vancomycin Dosing : Emphasis on Obesity. / Hall, Ronald G.; Payne, Kenna D.; Bain, Amy M.; Rahman, Anita P.; Nguyen, Sean T.; Eaton, Susan A.; Busti, Anthony J.; Vu, Stephen L.; Bedimo, Roger.

In: American Journal of Medicine, Vol. 121, No. 6, 06.2008, p. 515-518.

Research output: Contribution to journalArticle

Hall, RG, Payne, KD, Bain, AM, Rahman, AP, Nguyen, ST, Eaton, SA, Busti, AJ, Vu, SL & Bedimo, R 2008, 'Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity', American Journal of Medicine, vol. 121, no. 6, pp. 515-518. https://doi.org/10.1016/j.amjmed.2008.01.046
Hall RG, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA et al. Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity. American Journal of Medicine. 2008 Jun;121(6):515-518. https://doi.org/10.1016/j.amjmed.2008.01.046
Hall, Ronald G. ; Payne, Kenna D. ; Bain, Amy M. ; Rahman, Anita P. ; Nguyen, Sean T. ; Eaton, Susan A. ; Busti, Anthony J. ; Vu, Stephen L. ; Bedimo, Roger. / Multicenter Evaluation of Vancomycin Dosing : Emphasis on Obesity. In: American Journal of Medicine. 2008 ; Vol. 121, No. 6. pp. 515-518.
@article{443dc70283aa47d4a01bbb18d549187f,
title = "Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity",
abstract = "Background: There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight. Methods: This study was conducted at 2 tertiary care medical centers that did not have pharmacy-guided vancomycin dosing programs or other institutional vancomycin dosing policies or protocols. Patients who received vancomycin between July 1, 2003, and June 30, 2006, were stratified by body mass index and randomly selected from the computer-generated queries. Patients ≥18 years of age with a creatinine clearance of at least 60 mL/min who received vancomycin for at least 36 hours were included. Results: Data were collected on a random sampling of 421 patients, stratified by body mass index, who met the inclusion criteria. Most patients in each body mass index category received a fixed dose of vancomycin 2 g daily divided into 2 doses (underweight 82{\%}, normal weight 90{\%}, overweight 86{\%}, and obese 91{\%}). Adequate initial dosing (≥10 mg/kg/dose) was achieved for 100{\%} of underweight, 99{\%} of normal weight, 93.9{\%} of overweight, and 27.7{\%} of obese patients (P < .0001). Ninety-seven percent of underweight, 46{\%} of normal weight, 1{\%} of overweight, and 0.6{\%} of obese patients received ≥15 mg/kg/dose recommended by several Infectious Diseases Society of America guidelines. Pharmacists also failed to correct inadequate dosing because only 3.3{\%} of patients receiving less than 10 mg/kg/dose had their regimen changed in the first 24 hours of therapy. Conclusion: In this multicenter pilot study, obese patients routinely received inadequate empiric vancomycin using a lenient assessment of dosing. Greater efforts should be undertaken to ensure patients receive weight-based dosing because inadequate dosing can lead to subtherapeutic concentrations and potentially worse clinical outcomes.",
keywords = "Dosing, Obesity, Vancomycin",
author = "Hall, {Ronald G.} and Payne, {Kenna D.} and Bain, {Amy M.} and Rahman, {Anita P.} and Nguyen, {Sean T.} and Eaton, {Susan A.} and Busti, {Anthony J.} and Vu, {Stephen L.} and Roger Bedimo",
year = "2008",
month = "6",
doi = "10.1016/j.amjmed.2008.01.046",
language = "English (US)",
volume = "121",
pages = "515--518",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Multicenter Evaluation of Vancomycin Dosing

T2 - Emphasis on Obesity

AU - Hall, Ronald G.

AU - Payne, Kenna D.

AU - Bain, Amy M.

AU - Rahman, Anita P.

AU - Nguyen, Sean T.

AU - Eaton, Susan A.

AU - Busti, Anthony J.

AU - Vu, Stephen L.

AU - Bedimo, Roger

PY - 2008/6

Y1 - 2008/6

N2 - Background: There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight. Methods: This study was conducted at 2 tertiary care medical centers that did not have pharmacy-guided vancomycin dosing programs or other institutional vancomycin dosing policies or protocols. Patients who received vancomycin between July 1, 2003, and June 30, 2006, were stratified by body mass index and randomly selected from the computer-generated queries. Patients ≥18 years of age with a creatinine clearance of at least 60 mL/min who received vancomycin for at least 36 hours were included. Results: Data were collected on a random sampling of 421 patients, stratified by body mass index, who met the inclusion criteria. Most patients in each body mass index category received a fixed dose of vancomycin 2 g daily divided into 2 doses (underweight 82%, normal weight 90%, overweight 86%, and obese 91%). Adequate initial dosing (≥10 mg/kg/dose) was achieved for 100% of underweight, 99% of normal weight, 93.9% of overweight, and 27.7% of obese patients (P < .0001). Ninety-seven percent of underweight, 46% of normal weight, 1% of overweight, and 0.6% of obese patients received ≥15 mg/kg/dose recommended by several Infectious Diseases Society of America guidelines. Pharmacists also failed to correct inadequate dosing because only 3.3% of patients receiving less than 10 mg/kg/dose had their regimen changed in the first 24 hours of therapy. Conclusion: In this multicenter pilot study, obese patients routinely received inadequate empiric vancomycin using a lenient assessment of dosing. Greater efforts should be undertaken to ensure patients receive weight-based dosing because inadequate dosing can lead to subtherapeutic concentrations and potentially worse clinical outcomes.

AB - Background: There is a paucity of data available regarding the dosing of antimicrobials in obesity. However, data are available demonstrating that vancomycin should be dosed on the basis of actual body weight. Methods: This study was conducted at 2 tertiary care medical centers that did not have pharmacy-guided vancomycin dosing programs or other institutional vancomycin dosing policies or protocols. Patients who received vancomycin between July 1, 2003, and June 30, 2006, were stratified by body mass index and randomly selected from the computer-generated queries. Patients ≥18 years of age with a creatinine clearance of at least 60 mL/min who received vancomycin for at least 36 hours were included. Results: Data were collected on a random sampling of 421 patients, stratified by body mass index, who met the inclusion criteria. Most patients in each body mass index category received a fixed dose of vancomycin 2 g daily divided into 2 doses (underweight 82%, normal weight 90%, overweight 86%, and obese 91%). Adequate initial dosing (≥10 mg/kg/dose) was achieved for 100% of underweight, 99% of normal weight, 93.9% of overweight, and 27.7% of obese patients (P < .0001). Ninety-seven percent of underweight, 46% of normal weight, 1% of overweight, and 0.6% of obese patients received ≥15 mg/kg/dose recommended by several Infectious Diseases Society of America guidelines. Pharmacists also failed to correct inadequate dosing because only 3.3% of patients receiving less than 10 mg/kg/dose had their regimen changed in the first 24 hours of therapy. Conclusion: In this multicenter pilot study, obese patients routinely received inadequate empiric vancomycin using a lenient assessment of dosing. Greater efforts should be undertaken to ensure patients receive weight-based dosing because inadequate dosing can lead to subtherapeutic concentrations and potentially worse clinical outcomes.

KW - Dosing

KW - Obesity

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=43849083711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43849083711&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.01.046

DO - 10.1016/j.amjmed.2008.01.046

M3 - Article

VL - 121

SP - 515

EP - 518

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 6

ER -